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Objective. Most therapeutic treatments for auto-
immune arthritis rely on immunosuppressive drugs, which
have side effects. Although a previous study by our
group showed that specific ERK activation suppressed
immune responses, its application in a therapeutic setting
has never been tested. The aim of the present study was
to define the ERK-dependent immunosuppressive
mechanisms and to apply selective ERK activation for
the treatment of experimental inflammatory arthritis.
Methods. A constitutively active ERK activator
was coexpressed with a model antigen using lentivec-
tors. Immunosuppressive mechanisms were character-
ized at the level of dendritic cell (DC) function, differ-
entiation of antigen-specific Treg cells, and inhibition of
inflammatory T cells. Administration of the ERK acti-
vator with antigen as a strategy to suppress inflamma-
tory arthritis was tested in an experimental mouse
model.
Results. Selective ERK activation induced mouse
and human DCs to secrete bioactive transforming
growth factor , a process required for suppression of T
cell responses and differentiation of antigen-specific
Treg cells. Treg cells strongly proliferated after antigen
reencounter in inflammatory conditions, and these cells
exhibited antigen-dependent suppressive activities. In-
flammatory arthritis was effectively inhibited through
antigen-specific mechanisms. Importantly, this strategy
did not rely on identification of the initiating arthrito-
genic antigen. Equivalent mechanisms were demon-
strated in human monocyte–derived DCs, setting the
scene for a possible rapid translation of this approach
to patients with rheumatoid arthritis.
Conclusion. This strategy of selective ERK acti-
vation resulted in an effective therapeutic protocol, with
substantial advantages over DC or T cell vaccination.
Rheumatoid arthritis (RA) is an autoimmune
disease that is characterized by chronic joint inflamma-
tion, which eventually leads to bone destruction and a
significant decrease in life expectancy and quality of life.
This disease is thought to be caused by a loss of
tolerance toward autoantigens, although the specific
identities of these antigens are as yet unclear. RA is
currently treated with immunosuppressive drugs and
biologic agents such as methotrexate and infliximab.
However, these therapeutic agents induce a generalized
immunosuppression that increases the risk of infectious
diseases and cancer (1,2). Therefore, new therapeutic
approaches should be aimed at suppression of inflam-
mation and reestablishment of tolerance toward arthri-
togenic antigens without compromising the patient’s
immune system (1). However, the arthritogenic antigens
are yet to be clearly defined, and therefore these
antigen-specific therapeutic approaches should also be
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84amenable to redirection to circumvent the need to target
the pathogenic antigen. In this regard, some studies have
achieved an effective approach by engineering Treg cells
with well-defined specificities, in which these cells were
retargeted to suppress arthritis caused by a different
antigen (3). However, treatment of human patients with
large numbers of modified Treg cells is a rather chal-
lenging and cumbersome process (4).
Research in immune modulation has increased in
recent years, and a particular subset of dendritic cells
(DCs) has been shown to modulate immune responses
(5). Their suppressive activity is exerted through a
variety of mechanisms, including production of immu-
nosuppressive mediators and induction of Treg cell
differentiation (6–10). Many studies have used regula-
tory DCs for the treatment of autoimmune disease.
These DCs are generally differentiated ex vivo with a
variety of tolerogenic stimuli, particularly certain Toll-
like receptor and lectin ligands, immunosuppressive
mediators, and cytokines (7,11–14). These ligands trig-
ger a complex network of signaling pathways, some of
which have been implicated in immune tolerance (13–
17). Of particular note, the MAPK ERK has been
frequently implicated in the mechanisms of immunosup-
pression (11,18–20), although most of the evidence has
largely relied on the use of MEK chemical inhibitors
rather than specific activators. Possibly as a consequence
of this limitation, ERK tolerogenic activity has been
questioned in a number of cases, including studies of
experimental arthritis (21–23).
Manipulation of suppressive signaling pathways
in combination with antigen delivery could generate
potent antigen-specific tolerogenic DCs, which would
prevent generalized off-target immunosuppression. For
this purpose, we have developed an experimental ap-
proach to simultaneously deliver antigens and selectively
activate signaling pathways, which circumvents the need
for chemical inhibitors or agonists that trigger multiple
signaling pathways. In this study, we evaluated in detail
the role of selective ERK activation, through the use of
lentivectors for the expression of constitutively active or
dominant-negative mutants of MEK-1, the upstream
ERK kinase, as a strategy for the treatment of inflam-
matory arthritis.
MATERIALS AND METHODS
Cells and mice. The 293T cells were grown in Dulbec-
co’s modified Eagle’s medium with 10% fetal calf serum. A
transforming growth factor  (TGF) reporter cell line,
SMAD-GFP, was engineered by transducing 293T cells with
the lentivector pSIN-SMAD-GFP, as further described below.
Bone marrow–derived DCs (BMDCs) were prepared from
thymocyte antigen 1.2–positive (Thy1.2) C57BL/6 and
interleukin-10–knockout (IL-10
/) C57BL/6 mice (24).
Thy1.1 CD57BL/6 mice and Thy1.2 OT-I and OT-II mice,
which express a transgenic T cell receptor specific for H2-K
6–
restricted class I and class II ovalbumin epitopes, respectively,
were bred in-house. BMDCs were obtained using a previously
described method (25). Approval for the animal studies was
obtained from the University College London Animal Ethics
Committee. In separate experiments, DCs prepared from
human peripheral blood monocytes (PBMCs) were used for
lentiviral transduction and Treg cell induction or for stimula-
tion of CD8 T cells, as described previously (26,27).
Plasmids, lentivector production, titration, and cell
transduction. Dual lentivectors coexpressing MEK-1 mutants
along with green fluorescent protein (GFP) or invariant-chain
ovalbumin (IiOVA) were used (25). The hemagglutinin tag
was attached to the IiOVA C-terminus. A lentivector express-
ing GFP under the control of a promoter responsive to TGF
signaling (28) was constructed (pSIN-SMAD-GFP). A len-
tivector short hairpin RNA (shRNA) delivery system was
engineered by introducing a microRNA miR-30 sequence into
a synthetic chimeric intron derived from the plasmid pHy-
gEGFP (Clontech). TGF shRNA were selected using the
Hannon Laboratory design tool (see http://hannonlab.
cshl.edu/GH_shRNA.html). The shRNA in the miR-30 se-
quence were introduced within the synthetic intron, and this
was then inserted in the lentivector plasmid pDUAL-MEK-1
ED-IiOVA. The sequence of the shRNA used in the present
experiments (designated TGF-C) was 5-TGCTGTTGACA-
GTGAGCGACGGCAGCTGTACATTGACTTTTAGTGA-
AGCCACAGATGTAAAAGTCAATGTACAGCTGCCGG-
TGCCTACTGCCTCGGA-3. An inactive CD40-targeted
shRNA (designated CD40-B) was selected as the untargeted
control, and its sequence was 5-TGCTGTTGACAGTGAG-
CGAACAGACACTGTGAACCCAATCTAGTGAAGCCA-
CAGATGTAGATTGGGTTCACAGTGTCTGTGTGCCT-
ACTGCCTCGGA-3.
Lentivectors were produced and titrated by quantita-
tive polymerase chain reaction, as described previously (29).
Mouse BMDCs and human monocyte–derived DCs were
transduced using previously described methods (25–27,29). A
multiplicity of transduction between 5 and 30 was used to
modify the DCs.
Cell staining and flow cytometry. Surface and intra-
cellular staining were performed as described previously (25).
Stained cells were analyzed in a Becton Dickinson LSR flow
cytometer and FACSCalibur. The following anti-mouse anti-
bodies were purchased from eBioscience, together with the
appropriate isotype controls: biotinylated antibodies specific
for Thy1.1 and Thy1.2, phycoerythrin (PE)–conjugated anti-
CD25, anti-CD8, PE-Cy7–conjugated anti-CD4, allophycocya-
nin (APC)–conjugated anti-FoxP3, fluorescein isothiocyanate
(FITC)–conjugated anti–IL-10, APC-conjugated anti–
interferon- (anti-IFN), and FITC-conjugated anti–IL-17A.
Human PE-Cy7–conjugated anti-CD4 and APC-conjugated
anti-CD8 were purchased from BD PharMingen. Human
PE-conjugated CD25 and APC-conjugated anti-FoxP3 were
purchased from Miltenyi Biotec and eBioscience, respectively.
Vaccinations and T cell responses. All vaccination
experiments were repeated independently at least 3 times,
using groups of 5 mice that were vaccinated as previously
described (25). For DC vaccination, mice were vaccinated
SUPPRESSION OF INFLAMMATORY ARTHRITIS BY SPECIFIC ERK ACTIVATION 85subcutaneously, as described previously (25). When appropri-
ate, DCs were incubated with increasing concentrations of the
inhibitors U0126 and PD98059 (Cell Signaling Technology).
Class I OVA–specific enzyme-linked immunospot
(ELISpot) assays for IFN were performed as described
previously (25). Stainings for the OVA-specific class I pen-
tamer within CD3CD8 T cells were performed according
to the manufacturer’s protocol (Proimmune).
Murine antigen-induced arthritis (AIA). Induction of
arthritis with methylated bovine serum albumin (mBSA),
histologic staining of mouse knee sections with hematoxylin
and eosin, and scoring of histologic features of murine AIA
were performed as previously reported (3). Groups of 5 mice
were vaccinated with lentivectors, and AIA was initiated (3).
Knee sections were visualized using a Nikon Eclipse TS100
microscope with a 40/0.55 magnification objective, and im-
ages were obtained with a Nikon E950 digital camera. Histo-
logic scoring for the extent of joint destruction and inflamma-
tion was performed in a blinded manner, using a scale of 0–3.
A combined score was generated from the sum of the individ-
ual scores (maximum arthritis score of 6).
T cell purification and antigen-linked suppression
assay. CD4 T cells were purified from mouse spleens using
the Dynal Mouse CD4 Negative Isolation Kit (Invitrogen), and
CD4CD25 T cells were isolated using the CD4CD25
regulatory T cell isolation kit (Miltenyi Biotec). Human naive
CD4CD25 T cells and CD8 T cells were isolated from
human PBMCs obtained from at least 6 different donors (30).
An antigen-linked suppression assay was performed as de-
scribed previously (3), using carboxyfluorescein succinimidyl
ester (CFSE)–labeled OVA-specific OT-I CD8 cells as tar-
gets. Briefly, splenocytes from the OT-I–transgenic mouse
strain were labeled with CFSE, as described by the manufac-
turers (Invitrogen). Splenocytes were pulsed with 0.1 ng/l
class I OVA peptide (SINKFELL). Increasing numbers of
purified CD4CD25 T cells were added, and class II
OVA323–339 peptide was added at 2 g/ml when indicated. A
peptide from the hepatitis B virus core was used as a control
(31). Cell proliferation was analyzed with FlowJo software.
Allogeneic cocultures of human DCs with naive human
T cells were set up, and Treg cells were harvested and analyzed
after 3 days as previously described (30). An autologous
suppression assay with matured human DCs and purified Treg
cells was performed as described previously (32), using sorted
CD8 T cells as targets, in the absence or presence of
anti-CD3/anti-CD28 beads. Autologous sorted CD25
high T
cells were added at increasing ratios, and proliferation of the
cells was measured by determination of
3H-methyl-thymidine
uptake (Amersham) (32).
Statistical analysis. To analyze the ELISpot data,
normality was checked using the Kolmogorov-Smirnov test
(25). Pairwise comparisons for posterior probability were
performed using Tukey’s test. A minimum of 3 independent
experiments was performed with 5 mice per group. To com-
pare the mean fluorescence intensity from surface or intracell-
ular staining, with values adjusted for interexperimental vari-
ability, 2 different approaches were undertaken. In the first
approach, data were normalized relative to the value for
control untreated cells, and comparisons were performed as
described above. In the second approach, groups were com-
pared using raw data in a two-way analysis of variance with a
random criterium (experiments), and pairwise comparisons for
posterior probability were performed when required (25).
Data from antigen-linked suppression assays and histologic
scorings were analyzed as described previously (3).
RESULTS
Suppression of effector T cell expansion by selec-
tive ERK activation, leading to antigen-specific FoxP3
Treg cell differentiation. Autoimmune disorders such as
rheumatoid arthritis are caused by uncontrolled immune
responses toward autoantigens, a process that leads to
acute and chronic joint inflammation. For the treatment
of these disorders, effective immunosuppressive thera-
pies are necessary for the suppression of T cell responses
and Treg cell differentiation (1,3). We have previously
shown, using dual lentivectors, that coexpression of a
constitutively active MEK-1 mutant (MEK-1 NES ED,
or active MEK-1) with the model class II major histo-
compatibility complex fusion antigen IiOVA (MEK-1
ED–IiOVA construct) (Figure 1A) will lead to strong
inhibition of T cell responses and, possibly, to Treg cell
differentiation (25,33).
In this study, we wanted to selectively activate
ERK for the treatment of inflammatory arthritis. First,
we confirmed that a highly significant reduction of
OVA-specific CD8 T cells was achieved only when active
MEK-1 and IiOVA were simultaneously expressed from
the same lentivector backbone, with a reduction from
500 spots per million splenocytes down to 40 spots per
million splenocytes, as assessed by IFN ELISpot assay
(Figure 1A). Interestingly, OVA-specific CD8 responses
were significantly boosted when the ERK activator was
replaced by an inactive version (MEK-1 NES AA, or
inactive MEK-1) (Figure 1A).
Our data also suggested that antigen-specific
Treg cell differentiation was taking place when the ERK
activator and IiOVA were codelivered (25,33). To dem-
onstrate Treg cell differentiation, groups of congenic
Thy1.1 mice were vaccinated with each lentivector. One
day later, 10
6 purified OVA-specific CD4Thy1.2 OT-II
T cells per mouse were transferred intravenously, and
FoxP3 expression was assessed in the OT-II cells from the
draining inguinal lymph nodes. In the absence of OT-II
cell transfer, FoxP3 T cell expansion was observed only
after ex vivo OVA restimulation in mice vaccinated with
the ERK activator–IiOVA (Figure 1B). In contrast,
when OT-II cells were transferred, increased numbers of
FoxP3 Treg cells were evident in the lymph nodes,
without the need for OVA restimulation (Figure 1B).
Quantification of Thy1.2 T cells in the lymph
nodes and spleens of mice suggested that there was a
lack of significant proliferation only when the ERK
activator and IiOVA were coexpressed (Figure 1C). In
contrast, virtually all CD4 T cells were observed to be
86 ARCE ET ALFigure 1. ERK activation prevents T cell expansion and differentiates FoxP3CD4 T cells. A, Left, Schemes of lentiviral constructs coexpressing
MEK-1 ED (for active MEK-1) or MEK-1 AA (for inactive MEK-1) with the class II major histocompatibility complex fusion antigen invariant-chain
ovalbumin (IiOVA), or control constructs expressing green fluorescent protein (GFP) with or without IiOVA. Right, Ovalbumin (OVA)–specific CD8 T
cell responses, as determined by interferon- (IFN) enzyme-linked immunospot assay, in mouse spleens after lentivector vaccination. Bars show the
mean  SD results in 5 mice per group. B, FoxP3 expression in lymph node CD4CD25 T cells after lentivector vaccination, without or with OVA
restimulation and after intravenous transfer of OVA-specific CD4 OT-II cells without restimulation. Values are the percentage of FoxP3 T cells. C,
Thymocyte antigen 1.2 (Thy1.2) expression in lymph node CD4 T cells from Thy1.1 mice that received transferred Thy1.2 OT-II cells. Values are
the percentage of Thy1.2 T cells. D, Left, FoxP3 expression from lymph node Thy1.2CD4CD25 T cells in lentivector-vaccinated Thy1.1 mice after
transfer of CD4 OT-II cells or CD4CD25 OT-II cells. Values are the percentage of FoxP3 T cells. Right, FoxP3 expression in OT-II cells after
lentivector vaccination in 3 independent experiments (each represented as a differently shaded bar). Horizontal or vertical broken line indicates the cutoff
for positivity.   very significant difference (P 	 0.01);   highly significant difference (P 	 0.001). LTR  long terminal repeat; SFFV  spleen
focus–forming virus; UBIQ  ubiquitin; Ag  antigen.
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GFP-IiOVA or inactive MEK-1–IiOVA (Figure 1C).
Moreover, only the coexpression of active MEK-1 with
IiOVA resulted in a significant increase in FoxP3
expression within CD4CD25Thy1.2 OT-II cells
(Figure 1D). The same ERK-dependent FoxP3 induc-
tion was observed after transfer of 3  10
6 purified naive
CD25 OT-II cells, albeit at lower levels (Figure 1D).
Overall, these results indicate that ERK activation pre-
vented antigen-specific effector T cell expansion, result-
Figure 2. Antigen-specific FoxP3 Treg cells undergo expansion after antigen reen-
counter. A, Left, FoxP3 expression in lymph node CD4CD25 T cells following
lentivector vaccination (control constructs expressing GFP or GFP plus IiOVA, and
constructs with active MEK-1 [ED] or inactive MEK-1 [AA] plus IiOVA) and
rechallenge with OVA plus phosphate buffered saline (PBS) or Freund’s incomplete
adjuvant (IFA). Values are the percentage and mean fluorescence intensity (MFI) of
FoxP3 expression. Right, Expression of FoxP3 cells in lymph node Treg cells after
lentivector priming and OVA plus IFA boosting. B, Left, FoxP3 expression in purified
lymph node CD4CD25 T cells or spleen CD4CD25 T cells after active
MEK-1–IiOVA priming and OVA plus IFA boosting. Values are the percentage and
MFI of FoxP3 expression. Right, Inhibition of T cell proliferation according to treatment
group (no Treg cells, class II OVA peptide, or irrelevant peptide), as measured by the
division index and proliferation index. In A and B, the horizontal broken line indicates
the cutoff for positivity. C, CD8 IFN responses in peptide-pulsed OT-I mouse
splenocytes incubated with purified Treg cells at the indicated ratios. A class II OVA
peptide or an irrelevant peptide was present () or absent () in the assays with CD25
or CD25 cells. Bars in A–C show the mean  SEM results in 5 mice per group.   very
significant difference (P 	 0.01);   highly significant difference (P 	 0.001). See
Figure 1 for other definitions.
88 ARCE ET ALFigure 3. ERK-dependent immunosuppression is dependent on dendritic cell (DC)–derived transforming growth factor  (TGF). A, Left, CD8
T cell responses, as determined by IFN enzyme-linked immunospot (ELISpot) assay or OVA class I pentamer staining, after vaccination with
lentivector-modified DCs (or untransduced [UT] DCs as control) or after MEK inhibitor treatments. Right, FoxP3 expression in splenocyte
CD4CD25 T cells after lentivector vaccination. Values are the percentage and mean fluorescence intensity (MFI) of FoxP3 expression. B, Left,
FoxP3 expression in CD4CD25 OT-II cells cultured with transduced DCs. Values are the percentage and MFI of FoxP3 expression. Right, In
vitro Treg cell induction of FoxP3 expression in the DC–T cell cocultures, without or with TGF1 treatment at 5 ng/ml. C, Left (top), Scheme of
the lentivector short hairpin RNA (shRNA) delivery platform, highlighting the intron with microRNA miR-30 shRNA. Left (bottom), CD8 T cell
responses, as determined by IFN ELISpot assay, after vaccination with ex vivo lentivector-modified DCs and codelivery with TGF-targeted
shRNA (shTGF) or control shRNA (shCT). Right, FoxP3 expression in splenocyte CD4CD25 T cells after vaccination with lentivector-modified
DCs or shRNA, followed by OVA restimulation. Values are the percentage and MFI of FoxP3 expression. D, Left, OVA-specific CD8 responses,
as determined by IFN ELISpot assay, in mice vaccinated with lentivector-transduced interleukin-10–knockout (IL-10
/) DCs. Right, FoxP3
expression in splenocyte CD4CD25 T cells vaccinated with transduced IL-10
/ DCs. Values are the percentage and MFI of FoxP3 expression.
Horizontal broken lines indicate the cutoff for positivity. Bars in A–D show the mean  SEM.   significant difference (P 	 0.05);   very
significant difference (P 	 0.01);   highly significant difference (P 	 0.001). PBS  phosphate buffered saline; SD  splicing donor site; SA 
splicing acceptor site (see Figure 1 for other definitions).
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differentiation.
Strong boosting of antigen-specific FoxP3 Treg
cell expansion after a second antigen encounter under
inflammatory conditions. Treg cells are particularly
effective in inhibiting arthritis in mouse models (3).
Therefore, we tested whether these differentiated Treg
cells could expand in vivo after a second antigen encoun-
ter, a strategy that could be exploited to prevent arthri-
tis. Mice primed with lentivectors were rechallenged
with purified OVA either in phosphate buffered saline
(PBS) as control or in Freund’s incomplete adjuvant
(IFA). Four days later, Treg cells were quantified in the
draining lymph nodes.
Although FoxP3 T cell expression increased in
all vaccination groups challenged with OVA in PBS
(Figure 2A), only priming with the ERK activator
IiOVA resulted in vigorous endogenous FoxP3 Treg
cell expansion when OVA was administered under in-
flammatory conditions (OVA plus IFA) (Figure 2A).
ERK priming/OVA plus IFA boosting regularly resulted
in 70–75% of FoxP3 cells in CD4CD25 T cells
purified from the draining lymph nodes, but not in those
from the spleens (Figure 2B).
The suppressive activities of these cells were
tested in an antigen-linked suppression assay (3). CFSE-
labeled splenocytes from transgenic OT-I mice (OVA-
specific Thy1.2 CD8 T cells) stimulated with class I
OVA peptide were used as suppression targets. Purified
Thy1.1 Treg cells inhibited CD8 OT-I cell prolifer-
ation only when the class II OVA peptide was present, as
assessed by CFSE dilution after 3 days (Figure 2B). A
significant decrease was observed for both the division
index (representing the average number of cell divisions
from responding cells) and the proliferation index (rep-
resenting the average number of cell divisions that a cell
in the original population has undergone) (Figure 2B).
No significant inhibition was observed in the presence of
an irrelevant peptide or when the CD4CD25 coun-
terparts were used (results not shown).
Treg cell suppressive activity toward IFN re-
sponses was also tested by ELISpot assay after a 16-hour
incubation period. Interestingly, CD8 T cell IFN
responses were significantly inhibited by purified Treg
cells at all tested ratios only in the presence of class II
OVA peptide (Figure 2C). These results indicate that
Treg cells that expanded after antigen reencounter
exerted antigen-specific inhibitory activities toward
CD8 T cell proliferation and IFN responses.
Modulated DC function and differentiation of
tolerogenic DCs with TGF-dependent suppressive ac-
tivities after selective ERK activation. Subcutaneous
vaccination with lentivectors results in transduction of
DCs that subsequently migrate to draining lymph nodes
and present antigen to T cells (34,35). We hypothesized
Figure 4. Selective ERK activation differentiates regulatory human
monocyte–derived dendritic cells (huDC). A, Top, Construct with the
active (ED) or inactive (AA) MEK-1 and the indicated cytomegalovirus
(CMV) promoter and internal ribosome entry site (IRES) leading to GFP
expression. Bottom, Transforming growth factor  (TGF) activity in
supernatants of transduced huDC cultures, as assessed in SMAD-GFP
cells. B, FoxP3 expression, as assessed by flow cytometry, in T cells from
allogeneic huDC–naive CD4 T cell cocultures. DCs were left untrans-
duced (UT) or were transduced with the various lentivectors. T cells were
gated according to CD25 expression (CD25, CD25
intermediate [CD25
int],
and CD25
high). Values are the percentage and mean fluorescence inten-
sity (MFI) of FoxP3 expression. LPS  lipopolysaccharide-matured
DCs (positive control). C, Percentage of induced CD4CD25FoxP3
T cell expression in 6 different donor combinations (solid circles) using
transduced DCs with the indicated lentivectors. In A and C, horizontal
bars show the mean. D, Left, Proliferation of target CD8 T cells in a
representative experiment, as a function of the proportion of Treg cells
purified from the same cultures as described in B, with results expressed
as level of
3H-thymidine incorporation. Right, Proliferation of CD8 T
cells in response to stimulation with various percentages of Treg cells,
relative to that in unstimulated T cells. Bars show the mean  SEM data
from 3 independent experiments. LPS  T cells purified from LPS-
treated huDC/T cell cocultures; ED  T cells purified from ERK-
activated huDC/T cell cocultures.   significant difference (P 	 0.05);
  very significant difference (P 	 0.01);   highly significant
difference (P 	 0.001). See Figure 1 for other definitions.
90 ARCE ET ALthat DCs may be directly involved in ERK-dependent
immunosuppression, which could lead to differentiation
of immunosuppressive Treg cells. To characterize the
DC-dependent mechanisms involved in ERK toleroge-
nicity, we tested the capacity of ERK-activated BMDCs
to suppress in vivo immune responses.
ERK activation in DCs significantly decreased
OVA-specific CD8 T cell responses and expanded
FoxP3 Treg cells, while ERK inhibition increased
responses (Figure 3A). Similarly, DCs expressing IiOVA
and treated with the MEK chemical inhibitor U0126, but
not those treated with the inhibitor PD98059, had sig-
nificantly increased CD8 responses (Figure 3A). These
results confirm that ERK-activated DCs are immuno-
suppressive, while expression of the MEK-1 dominant-
negative mutant enhances their immunogenicity.
The capacity of ERK-activated DCs to directly
expand antigen-specific Treg cells from OT-II cells was
alsotested.Interestingly,theexpressionofCD4CD25
FoxP3 OT-II cells increased only when active MEK-1–
IiOVA was expressed or when IiOVA-expressing DCs
were treated with TGF, a well-known FoxP3 inducer
(36,37) (Figure 3B). No conversion to FoxP3 Treg cells
was observed in CD4 T cells from nontransgenic mice
(results not shown). These results indicate that ERK-
activated DCs expanded FoxP3 T cells from antigen-
specific T cells, although the effect was less efficient than
that after in vivo lentivector administration of the ERK
activator.
Previously, we have shown that selective ERK
activation in DCs increased TGF expression (25). We
functionally confirmed these results by engineering a
293T cell line containing a well-characterized TGF-
responder promoter (28) driving GFP expression
(SMAD-GFP 293T cells) (results not shown). TGF
bioactivity was evident in supernatants from ERK-
activated BMDCs (in the order of 200 pg/million trans-
duced DCs), in contrast to the supernatants from inac-
tive MEK-1– or GFP-expressing DCs (	10 pg/million
transduced DCs) (results not shown). To clarify the
contribution of TGF to ERK-induced immunosuppres-
sion, we developed a lentivector-based codelivery plat-
Figure 5. In vivo delivery of the ERK activator effectively inhibits murine antigen-induced arthritis
without targeting the arthritogenic antigen. A, Left, Experimental vaccination regimen used to induce
arthritis. Arrows at the top indicate the day on which each step took place. Middle, Extent of inflammation
after intraarticular challenge with methylated bovine serum albumin (mBSA) in the presence (right knee)
or absence (left knee) of OVA, following vaccination with the constructs containing phosphate buffered
saline (PBS), the inactive (AA) or active (ED) ERK forms with IiOVA, or GFP with IiOVA. Right, Extent
of inflammation in experiments with the ERK activator (ED) after intraarticular challenges performed in
the absence () or presence () of OVA. B, Left, FoxP3 expression in CD4CD25 T cells, as assessed
by flow cytometry, from draining lymph nodes of mice after vaccination with the indicated lentivectors and
induction of antigen-induced arthritis (AIA). Analyses were performed on day 4 postchallenge. Values are
the percentage and mean fluorescence intensity (MFI) of FoxP3 expression. Middle, FoxP3 expression
in CD4CD25 T cells from draining lymph nodes after lentivector vaccination and induction of AIA.
Right, Extent of knee inflammation after OVA-specific Treg cell transfer to mBSA-sensitized mice before
challenge. Bars show the mean  SEM. The horizontal broken lines indicate the cutoff for positivity.  
significant difference (P 	 0.05);   very significant difference (P 	 0.01);   highly significant
difference (P 	 0.001). CFA  Freund’s complete adjuvant (see Figure 1 for other definitions).
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IiOVA (Figure 3C). Modified DCs were administered to
naive mice, and it was found that delivery of a TGF-
specific shRNA, but not a control shRNA, completely
abrogated the ERK-mediated CD8 T cell suppressive
activity and FoxP3 Treg cell induction (Figure 3C).
We previously have shown that ERK-activated
DCs in culture did not increase IL-10 secretion (25),
although the possibility cannot be discarded that DC-
derived IL-10 may still play a role in vivo. Interestingly,
selective ERK activation in IL-10
/ BMDCs very effi-
ciently suppressed CD8 T cell responses and induced
expression of FoxP3 T cells (Figure 3D). These results
suggest that DC-induced immunosuppression by ERK
activation was dependent on TGF bioactivity, but
independent of IL-10.
Generation of regulatory human DCs by selective
ERK activation. Our results in murine cells demon-
strated that ERK activation resulted in differentiation of
regulatory DCs with immunosuppressive capacity, lead-
ing to Treg cell expansion. To find out whether equiva-
lent mechanisms are present in human cells, we next
tested whether ERK activation could differentiate reg-
ulatory DCs from human PBMC–derived DCs. The
demonstration of this point is of particular importance
for the application of our therapeutic strategy to patients
Figure 6. Prevention of joint destruction by delivery of the ERK activator (A and B), and working model for ERK-dependent
immunosuppression (C). A, Photomicrographs show hematoxylin and eosin–stained mouse knee joint sections after challenge
with methylated bovine serum albumin (mBSA) and OVA. Top panels, Articular cartilage and bone sections. Bottom panels,
Articular capsule. In the control group (intraarticular injection with mBSA  OVA in naive mice), the joints show an absence
of inflammation and a lack of cellular infiltration. In the group vaccinated with the ERK activator and IiOVA (MEK1
ED–IiOVA) before induction of antigen-induced arthritis (AIA), the integrity of the articular cartilage and bone is evident,
with limited cellular infiltration in the articular capsule (arrow). In the group vaccinated with the inactive MEK-1 mutant and
IiOVA (MEK1 AA–IiOVA) before induction of AIA, destruction of articular cartilage and bone is evident (arrowheads), with
extensive cellular infiltration (arrows). Original magnification  40. B  trabecular bone; C  articular cartilage; AC 
articular capsule. B, Histologic scores were determined to measure the extent of joint destruction and inflammation after
lentivector vaccination. Bars show the mean  SEM results in 5 mice per group.   highly significant difference (P 	 0.001).
C, Left, ERK-activated immature dendritic cells (iDC) present antigen under suboptimal conditions to T cells, leading to
reduced CD8 T cell expansion. Transforming growth factor  (TGF) drives antigen-specific Treg cell differentiation rather
than expansion of effector CD4 T cells. Right, A second antigen exposure under inflammatory conditions drives strong Treg
cell proliferation, with antigen-specific suppressive activities. MHC-I  class I major histocompatibility complex.
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encoding ERK modulators under the control of a cyto-
megalovirus promoter followed by an internal ribosome
entry site leading to GFP expression (Figure 4A). These
lentivectors were used because the spleen focus–forming
virus and ubiquitin promoters were found to be particularly
inefficient in human PBMC–derived DCs.
ERK-activated human PBMC–derived DCs ex-
hibited an immature phenotype (results not shown). In
addition, high levels of TGF bioactivity were evident,
as assessed in SMAD-GFP cells, only when active MEK-1
was expressed (Figure 4A), while no changes in the levels
of IL-6, IL-12p70, and IL-10 were observed (results not
shown).
To test the capacity of ERK-activated human
PBMC–derived DCs to differentiate Treg cells from
naive T cells, we used allogeneic DC–T cell cocultures to
circumvent the need for specific antigen recognition. A
significant increase in the expression of CD4CD25
high
FoxP3 T cells as well as in FoxP3 expression was evi-
dent only when human PBMC–derived DCs were ex-
pressing the ERK activator, while a decrease was observed
when the inactive MEK-1 mutant was used (Figures 4B
and C); as a positive control, lipopolysaccharide-treated
human PBMC–derived DCs were used to induce Treg
cell differentiation, as described previously (38).
To eliminate the possibility that FoxP3 T cells
generated by selective ERK activation were effector
cells, their suppressive capacity was tested utilizing an
autologous suppression assay (30,32). Briefly, matured
human PBMC–derived DCs and sorted CD8 T cells
from a single donor were cocultured in the presence of
anti-CD3/anti-CD28 beads. Sorted CD4CD25
high T
cells purified from ERK-activated human PBMC–derived
DC–T cell cocultures significantly inhibited CD8 T cell
proliferation, as measured by
3H-thymidine incorpora-
tion(Figure4D).Therefore,ERK-activatedhumanPBMC–
derived DCs induced functional CD4CD25FoxP3 T
cell differentiation, leading to suppressive activities.
Prevention of AIA without targeting the arthri-
togenic antigen after in vivo administration of the ERK
activator. Our results showed that selective ERK activa-
tion was clearly immunosuppressive, leading to differen-
tiation of regulatory DCs and Treg cells. We next
applied our strategy to a well-established inflammatory
arthritis model in mice, the AIA model (3). This model
relies on sensitization with mBSA, followed by intraar-
ticular challenge to the knee joint with mBSA in the
presence (right knee) or absence (left knee) of the
tolerizing protein. Direct lentivector administration or
DC vaccination was applied before mBSA sensitization
(Figure 5A). Although DC vaccination yielded similar
results, we chose to focus on direct lentivector adminis-
tration in further studies, due to its simplicity.
The extent of inflammation, which was measured
as the percent change in knee swelling, was significantly
reduced (mean values lower than 5%) only when the
ERK activator and IiOVA were coadministered, but this
did not occur in control groups, such as delivery of the
ERK inhibitor with IiOVA (Figure 5A). The ERK-
targeted antigen (OVA) caused this therapeutic effect,
because it was only observed when OVA was coinjected
with mBSA (Figure 5A). This result demonstrated that
antigen-specific tolerance was achieved, and excluded
the possibility of off-target tolerization toward mBSA.
Interestingly, inhibition of inflammation was also ob-
served in the contralateral knee (challenge with mBSA
alone) (Figure 5A).
Strong FoxP3 Treg cell proliferation was ob-
served in the draining lymph nodes only after treatment
with the ERK activator and IiOVA (Figure 5B), which is
consistent with our earlier results (Figure 2). To test
whether Treg cells were responsible for the therapeutic
effects, 10
6 purified OVA-specific Treg cells per mouse
(Figure 2B) were intravenously transferred before the
induction of AIA. Transfer of OVA-specific Treg cells
strongly inhibited knee inflammation when OVA was
provided along with mBSA (Figure 5B). Interestingly,
the therapeutic effects in the contralateral knee were
lost (Figure 5B), suggesting that additional suppressive
mechanisms might take place after direct lentivector
administration of the ERK activator. In addition to Treg
cell expansion, selective ERK activation strongly reduced
the expression of inflammatory T cell subsets, particu-
larly IFNIL-17 double-positive cells, the expression
of which was completely abrogated (results not shown).
Histopathologic studies confirmed that direct ad-
ministration of the ERK activator and IiOVA protected
joints from inflammation and bone destruction after
intraarticular challenge, when OVA was provided with
mBSA (Figure 6A). In contrast, when the ERK inhibitor
was administered instead, articular cartilage/bone de-
struction and extensive cellular infiltration in the artic-
ular capsule were evident, together with a significant
increase in the arthritis score (Figures 6A and B).
DISCUSSION
To our knowledge, this is the first time that
selective activation of a single intracellular signaling
pathway has been used to establish antigen-driven im-
munosuppression that effectively inhibits inflammatory
arthritis. We have demonstrated that the ERK pathway
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rather than MEK chemical inhibitors. Simultaneous
ERK activation and antigen expression inhibited effec-
tor T cell responses, leading to antigen-specific FoxP3
Treg cell differentiation. These Treg cells strongly ex-
panded in vivo after a second antigen encounter in
inflammatory conditions, and exerted inhibitory activi-
ties in the presence of the specific class II epitope
peptide. These results support a mechanism in which
antigen recognition by Treg cells is required or, at least,
highly enhances their suppressive activity (3). Interest-
ingly, rechallenge with OVA in the absence of adjuvant
also resulted in efficient expansion of FoxP3 Treg cells
independent of the vaccination regimen with lentivec-
tors. It is tempting to speculate that this Treg cell expansion
could be the underlying mechanism by which administra-
tion of purified proteins in the absence of adjuvants
results in tolerance, as opposed to immunization.
Direct lentivector administration of the ERK
activator resulted in strong immunosuppression, even
though the lentivectors were not per se specifically
targeted to DCs. However, we and others have shown
that subcutaneous lentivector vaccination transduces skin-
derived DCs, which migrate to draining lymph nodes
and present antigens to T cells (34,35). Accordingly, our
findings showed that ERK activation in BMDCs resulted
in generation of immunosuppressive DCs, which also
inhibited inflammatory arthritis. Interestingly, ERK in-
hibition also increased the immunogenicity of the lenti-
viruses and DCs. In vivo, the ERK-dependent DC
suppressive activity, including FoxP3 T cell differenti-
ation, relied completely on DC-derived TGF, but not
on IL-10. Many studies using MEK chemical inhibitors
have linked ERK activation with IL-10 secretion (39).
However, we have never observed increased IL-10 pro-
duction after selective ERK activation in DCs (25).
Furthermore, unlike the indispensable role of TGF,w e
found that DC-derived IL-10 was not needed in order
for ERK-dependent immunosuppression to occur.
On the basis of our results, we propose a model
for ERK tolerogenic activity (Figure 6C). In the first
stage, ERK activation keeps DCs in an immature stage.
Suboptimal antigen presentation combined with in-
creased secretion of bioactive TGF inhibits CD8 T cell
expansion and leads to Treg cell differentiation. In the
second stage, these Treg cells strongly proliferate after
antigen reencounter in inflammatory conditions, thus
inhibiting inflammatory T cell responses.
Importantly, selective ERK activation differenti-
ated regulatory human PBMC–derived DCs that had the
capacity to expand functional FoxP3 Treg cells, which
could be used to suppress autoimmune arthritis in humans.
ERK-activated human PBMC–derived DCs exhibited an
immature phenotype, with high levels of bioactive TGF
secretion. ERK-activated human PBMC–derived DCs
significantly induced differentiation of CD4CD25
high
FoxP3 T cells from allogeneic naive T cells. Functional
human FoxP3 Treg cells are restricted to the CD25
high
population (40), and in this study, we demonstrated their
capacities to inhibit proliferation of activated CD8 T
cells. The mechanisms by which these induced Treg cells
inhibit CD8 T cell proliferation in the presence of ERK-
activated human PBMC–derived DCs are currently un-
der investigation. These results indicate that selective
ERK activation could be applied for the treatment of
autoimmune arthritis in humans. Accordingly, experi-
mental inflammatory arthritis was effectively inhibited in
a mouse model. Moreover, even though antigen
(OVA)–driven immunosuppression was achieved, we
demonstrated that direct targeting of the arthritogenic
antigen (mBSA) was not required. This could be of
particular importance because arthritogenic antigens are
not well characterized and may vary between patients.
Most cellular-based therapies rely on ex vivo
modification of large numbers of cells from the patients.
These strategies are promising, although they may be
cumbersome and expensive (4,41). In this study, direct
lentivector administration of the ERK activator resulted
in an effective, straightforward protocol with a signifi-
cant improvement over strategies involving DC or T cell
vaccination.
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